• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Qiagen Introduce Tool For Customizing Digital PCR Assays, NGS Panels

    PHARMABIZ

    Qiagen Launches Tools for Customizing PCR Assays & NGS Panels

    GLOBENEWSWIRE

    QIAGEN Partners with McGill to Advance Microbiome Research

    GLOBENEWSWIRE

    Diagnostics firm Qiagen reports rise in third-quarter revenue

    REUTERS

    Qiagen Delivers Solid Q3 2024 Growth, Increases EPS Outlook

    GLOBENEWSWIRE

    Qiagen Receives FDA Clearance for QIAstat-Dx Meningitis Panel

    GLOBENEWSWIRE

    QIAGEN Receives FDA Clearance for QIAstat-Dx Mini Panel

    GLOBENEWSWIRE

    Qiagen to release results for Q3 2024 and hold webcast

    GLOBENEWSWIRE

    Qiagen Expands Automated Liquid Biopsy Portfolio In Oncology

    GLOBENEWSWIRE

    Qiagen Leads Global TB Summit 2024 As Disease Reemerges

    GLOBENEWSWIRE

    QIAGEN Launches QIAcuityDx Digital PCR System For Oncology

    GLOBENEWSWIRE

    Qiagen Receives European IVDR Certification For QIAstat-Dx

    GLOBENEWSWIRE

    PreAnalytiX Launches Urine Liquid Biopsy Solution

    GLOBENEWSWIRE

    QIAGEN Bode Partner On GEDmatch PRO Forensic Database

    GLOBENEWSWIRE

    Qiagen Expands QIAcuity With 100 New Assays

    GLOBENEWSWIRE

    QIAGEN And Bio-Manguinhos Partner For Malaria And Dengue Detection

    GLOBENEWSWIRE

    QIAGEN And Lilly Partner On Alzheimer`s Disease Test Panel

    GLOBENEWSWIRE

    QIAGEN N.V. launches non-US offering of net share settled convertible bonds

    GLOBENEWSWIRE

    QIAGEN Announces Successful Placement of New Convertible Bonds

    GLOBENEWSWIRE

    QIAGEN Announces Conversion Price for New Convertible Bonds

    GLOBENEWSWIRE

    Qiagen, AstraZeneca Expand Diagnostic Partnership To Chronic Diseases

    FIERCE BIOTECH

    QIAGEN Expands QIAstat-Dx Into Precision Medicine For Chronic Diseases

    GLOBENEWSWIRE

    QIAGEN delivers solid performance and exceeds outlook for Q2 2024

    GLOBENEWSWIRE

    QIAGEN to enhance the identification of human remains of Indigenous people

    GLOBENEWSWIRE

    QIAGEN N.V. to release results for Q2 2024 and hold webcast

    GLOBENEWSWIRE

    QIAGEN welcomes new U.S. guidelines for use of QuantiFERON-TB in tuberculosis

    GLOBENEWSWIRE

    QIAGEN Announces 2028 Strategy For Solid Profitable Growth

    GLOBENEWSWIRE

    QIAGEN`s QCI Interpret Accelerates NGS Clinical Reporting Turnaround

    GLOBENEWSWIRE

    QIAGEN Publishes 2023 Sustainability Report On ESG Progress

    GLOBENEWSWIRE

    QIAGEN launches new QIAcuity digital PCR assays for microbial applications

    GLOBENEWSWIRE

    QIAGEN To Discontinue NeuMoDx PCR System, Support Customer Transition

    GLOBENEWSWIRE

    QIAGEN: Digital PCR Assay Tool For QIAcuity, GeneGlobe Customization

    GLOBENEWSWIRE

    QIAGEN Expands Gastrointestinal Syndromic Test Menu In US

    GLOBENEWSWIRE

    QIAGEN Myriad HRD Test For Research Companion Diagnostics

    GLOBENEWSWIRE

    QIAGEN Launches Library Prep Kit For Multiomics, Precision Medicine

    GLOBENEWSWIRE

    QIAGEN Gets European IVDR Certification For Clinical Decision Support Software

    GLOBENEWSWIRE

    US FDA clears Qiagen’s QIAstat-Dx respiratory syndromic testing panel

    PHARMABIZ

    QIAGEN Gets FDA Clearance For Respiratory Syndromic Testing Panel

    GLOBENEWSWIRE

    QIAGEN Partners with FBI on Digital PCR Assay for Forensics

    GLOBENEWSWIRE

    Qiagen enhances bioinformatics workflows with new secondary analysis

    BIOSPECTRUM ASIA

    QIAGEN Enhances Oncology, Inherited Disease Bioinformatics

    GLOBENEWSWIRE

    QIAGEN Q1 2024 Results Ahead of Outlook, Tracking FY2024 Guidance

    GLOBENEWSWIRE

    QIAGEN Expands TB Portfolio with New NGS Panel

    GLOBENEWSWIRE

    QIAGEN N.V. to Release Results for Q1 2024 and Hold Webcast

    GLOBENEWSWIRE

    QIAGEN strengthens its portfolio, showcasing latest product at AACR

    GLOBENEWSWIRE

    QIAGEN introduces QIAstat-Dx Analyzer 2.0 with remote test results access

    GLOBENEWSWIRE

    QIAGEN partners with International Panel Physicians Association to increase

    GLOBENEWSWIRE

    QIAGEN partners with Physicians to increase awareness of tuberculosis

    GLOBENEWSWIRE

    QIAGEN announces Form 20-F annual report filing for 2023 results

    GLOBENEWSWIRE

    QIAGEN launches AI-derived biomedical knowledge base

    GLOBENEWSWIRE

    QIAGEN earns ACT Label for new eco-friendlier QIAwave products

    GLOBENEWSWIRE

    QIAGEN exceeds outlook for Q4 2023

    GLOBENEWSWIRE

    Qiagen announces partnership with Penn State University

    BIOSPECTRUM ASIA

    QIAGEN announces details for completion of synthetic share repurchase

    GLOBENEWSWIRE

    QIAGEN N.V. to release results for Q4 2023 and hold webcast

    GLOBENEWSWIRE

    QIAGEN receives FDA clearance of NeuMoDx CT/NG Assay for use on both NeuMoDx 96

    GLOBENEWSWIRE

    QIAGEN announces plans to return approximately $300 million to shareholders

    GLOBENEWSWIRE

    QIAGEN to accelerate investments into QIAGEN Insights bioinformatics business

    GLOBENEWSWIRE

    QIAGEN expands business in Middle East with new regional headquarters

    GLOBENEWSWIRE

    DNA Labs International solves significant cold cases with QIAGEN workflow

    GLOBENEWSWIRE

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.